Lung Ultrasound Score and Pediatric Intensive Care Outcomes (LUS-PICO)

Sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias (Other)
Overall Status
Completed
CT.gov ID
NCT04660448
Collaborator
(none)
650
1
12
54.4

Study Details

Study Description

Brief Summary

Bedside lung ultrasonography helps to obtain reliable clinical information about lung aeration, that has been categorized by means of the so-called lung ultrasound score (LUS). In critically ill adults, LUS has been related with the outcome both in patients with respiratory and some non-respiratory conditions. Pediatric studies about lung aeration have been done mainly on postoperative cardiac patients and infants with bronchiolitis. In this prospective, observational, multicenter, feasibility and diagnostic accuracy study, we will explore the degree of lung aeration impairment as a potential outcome predictor in critically ill children with a variety of underlying conditions. Children from 1 month to 18 years of age admitted to PICU will be recruited and LUS will be calculated at two time points: at 12 ± 6 hours and at 48-72 hours. Univariate and multivariate statistical analysis will be performed in order to ascertain the outcome influence of clinical factors in general and LUS in particular.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Bedside lung ultrasound examination

Detailed Description

Lung aeration can be assessed at the bedside by means of lung ultrasound, a non-invasive, quick, simple, and reproducible technique. It provides semiquantitative information about the amount of extravascular lung water (EVLW), which correlates with lung aeration. Accumulation of EVLW occurs secondarily to acute lung injury due to infection, inflammation or fluid overload. Lung aeration, measured by the lung ultrasound score (LUS), has been associated to patients' outcome in several studies in adult patients, suggesting that critically ill subjects showing higher degree of aeration loss have a worse outcome. This fact has been shown not only in patients with baseline respiratory conditions (for example in severe acute respiratory syndrome coronavirus 2), but also in adults with non-respiratory conditions, such as shock and in high-risk postoperative patients. Furthermore, animal studies have suggested that information obtained through lung ultrasonography may precede clinical signs and could help anticipate focused treatment.

To date, pediatric studies addressing the potential relationship between LUS and the outcome of critically ill children are scarce and limited to postoperative cardiac patients and infants with bronchiolitis.

In our research, children from 1 month to 18 years of age admitted to pediatric intensive care unit (PICU) who fulfill inclusion criteria will be recruited and will undergo point of care lung ultrasound examination at 12 ± 6 hours and at 48-72 hours from admission. Clinical data will be recorded and LUS will be calculated. The main objective of our study is to assess the potential role of LUS (as a semiquantitative indicator or lung aeration) as a feasible and reliable outcome prediction tool in children admitted to PICU. Secondary objectives will include to analyze the correlations between LUS and the need and length of ventilatory support, inflammatory and cardiac markers, hydric balance, renal replacement therapies requirement, and validated prognostic scales, as well as age, underlying disease, co-morbidities, length-of-stay, and other clinical characteristics of included children.

Patients with acute respiratory distress syndrome (ARDS) or shock during PICU admission time will also undergo additional lung ultrasound examinations at 12 ± 6 hours and at 48-72 hours from ARDS or shock diagnosis, as these subgroups represent a very specific and severe cohort of patients, which merits further analysis.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
650 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Lung Ultrasound Score and Pediatric Intensive Care Outcomes: a Prospective Observational Multicenter Study
Actual Study Start Date :
Dec 1, 2020
Actual Primary Completion Date :
Mar 31, 2021
Actual Study Completion Date :
Nov 30, 2021

Outcome Measures

Primary Outcome Measures

  1. Requirement of invasive mechanical ventilation for more than 96 hours [96 hours]

    To evaluate the correlation of LUS obtained in the first 72 hours of admission with the need of invasive ventilatory support for over 96 hours. A comparison between patients with a respiratory condition versus non-respiratory condition as the cause of admission will be performed.

Secondary Outcome Measures

  1. Correlation between lung aeration and bedside inflammatory markers [72 hours]

    To evaluate the relation between lung aeration estimated by LUS and bedside inflammatory markers (C reactive protein, interleukin-6, procalcitonin, ferritin)

  2. Correlation between lung aeration and bedside cardiac markers [72 hours]

    To evaluate the relation between lung aeration estimated by LUS and bedside cardiac markers (Brain natriuretic peptide, N-terminal proBNP, troponin, cystatin C)

  3. Correlation between lung aeration and hydric balance and the need of renal replacement therapy [72 hours]

    To evaluate the relation between lung aeration estimated by LUS and hydric balance and the need of renal replacement therapy

  4. Correlation between LUS and pediatric mortality scales [72 hours]

    To evaluate the relation between lung aeration and three prognostic indexes: pediatric risk of mortality (PRISM) III, pediatric sequential organ failure assessment (pSOFA), pediatric logistic organ dysfunction 2 (PELOD-2). It will also be assessed whether LUS may add any prognostic capacity to these scales.

  5. Comparison of LUS calculation exploring 12 areas versus 8 areas [72 hours]

    To compare the prognostic ability of LUS calculated employing 12 lung zones versus LUS obtained using 8 zones (anterior and lateral areas exclusively)

Other Outcome Measures

  1. Utility of LUS in patients diagnosed with acute respiratory distress syndrome (ARDS) after 24 hours of admission [72 hours]

    All previously specified objectives will be evaluated in children diagnosed with ARDS. In those cases, LUS will be calculated at 12 +/- 6 hours and 72 hours from ARDS diagnosis.

  2. Utility of LUS in patients diagnosed with shock after 24 hours of admission [72 hours]

    All previously specified objectives will be evaluated in children diagnosed with shock after 24 hours from admission. In those cases, LUS will be calculated at 12 +/- 6 hours and 72 hours from shock diagnosis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children 1 month to 18 years-old admitted to PICU due to an acute condition
Exclusion Criteria:
    • Children admitted to PICU to perform a procedure or to adjust a certain treatment (eg, home ventilatory support).
    • Children with chronic pulmonary pathology (cystic fibrosis, bronchopulmonary dysplasia, etc…)
    • Preoperative admissions in a stable condition (eg. Patient admitted previously to cardiac surgery)
    • Inability to obtain interpretable ultrasonographic images due to bad ultrasonographic window
    • Non disponibility of investigator
    • High frequency ventilation
    • Lack of clinical data

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Universitario Central de Asturias (HUCA) Oviedo Principado De Asturias Spain 33011

Sponsors and Collaborators

  • Fundación para la Investigación Biosanitaria del Principado de Asturias

Investigators

  • Study Chair: Guillermo M. Albaiceta, MD PhD, HUCA-FINBA. Universidad de Oviedo
  • Principal Investigator: Juan Mayordomo-Colunga, MD PhD, HUCA-FIBA

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fundación para la Investigación Biosanitaria del Principado de Asturias
ClinicalTrials.gov Identifier:
NCT04660448
Other Study ID Numbers:
  • FINBA_CritLab_3
First Posted:
Dec 9, 2020
Last Update Posted:
Apr 12, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2022